Aller au contenu

Publications scientifiques

  • article Pouliot F, Lodde M, Besançon M, Castonguay V, Morin-Coulombe A, Fradet V, Fradet Y, Lacombe L, Lévesque É and Marcoux N, Toren P, April G, Arsenault F, Beaulieu A, Singbo N, Veilleux C, Tremblay-Boily M, Tremblay V, Buteau FA, Beauregard JM

    Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases t…

    Can Urol Assoc J 2026.

    DOI PUBMED
  • article Soliman C, Sathianathen N, Corcoran NM, Wuethrich PY, Furrer MA and

    International Multicentre Analysis of Perioperative Complications Following Major Urologic Oncologic Surgery: Early Results from More than 130 000 Procedures from the CAMUS Colla…

    Eur Urol Focus 2026.

    DOI PUBMED
  • article Powles T, Csőszi T, Loriot Y, Matsubara N, Geczi L, Cheng SY, Fradet Y, Alva A, Oudard S, Vulsteke C, Morales-Barrera R, Fléchon A, Gunduz S, Liu CC, Moreno BH, Bavle A and Özgüroğlu M

    Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study

    Clin Genitourin Cancer 23 (1), 2025.

    DOI PUBMED
  • article Yamaguchi TN, Houlahan KE, Zhu H, Kurganovs N, Livingstone J, Fox NS, Yuan J, Sietsma Penington J, Jung CH, Schwarz T, Jaratlerdsiri W, van Riet J, Georgeson P, Mangiola S, Taraszka K, Lesurf R, Jiang J, Chow K, Heisler LE, Shiah YJ, Ramanand SG, Clarkson MJ, Nguyen A, Espiritu SMG, Stuchbery R, Jovelin R, Huang V, Bell C, O'Connor E, McCoy PJ, Lalansingh CM, Cmero M, Salcedo A, Chan EKF, Liu LY, Stricker PD, Bhandari V, Bornman RMS, Sendorek DHS, Lonie A, Prokopec SD, Fraser M, Peters JS, Foucal A, Mutambirwa SBA, Mcintosh L, Orain M, Wakefield M, Picard V, Park DJ, Hovington H, Kerger M, Bergeron A, Sabelnykova V, Seo JH, Pomerantz MM, Zaitlen N, Waszak SM, Gusev A, Lacombe L, Fradet Y, Ryan A, Kishan AU, Lolkema MP, Weischenfeldt J, Têtu B, Costello AJ, Hayes VM, Hung RJ, He HH, McPherson JD, Pasaniuc B, van der Kwast T, Papenfuss AT, Freedman ML, Pope BJ, Bristow RG, Mani RS, Corcoran NM, Reimand J, Hovens CM, Boutros PC

    The Germline and Somatic Origins of Prostate Cancer Heterogeneity

    Cancer Discov 15 (5), 2025.

    DOI PUBMED
  • article Segovia C, Desrosiers V, Khadangi F, Robitaille K, Armero VS, D'Astous M, Khelifi G, Bergeron A, Hussein S, Richer M, Bossé Y, Fradet Y, Fradet V, Bilodeau S

    A versatile and efficient method to isolate nuclei from low-input cryopreserved tissues for single-nuclei transcriptomics

    Sci Rep 15 (1), 2025.

    DOI PUBMED
  • article Kulkarni GS, Black PC, Sridhar SS, Zlotta AR, Shayegan B, Rendon RA, Chung P, van der Kwast T, Alimohamed N, Fradet Y, Kokorovic A, Cury FL, Kassouf W, Bossé D, Izard J, McAlpine K

    2025 Canadian Urological Association Expert Report: Muscle-invasive bladder cancer

    Can Urol Assoc J 19 (1), 2025.

    DOI PUBMED
  • article Xu X, Zhu H, Hugh-White R, Livingstone J, Eng S, Zeltser N, Wang Y, Pajdzik K, Chen S, Houlahan KE, Luo W, Liu S, Sheng M, Guo WY, Arbet J, Song Y, Wang M, Zeng Y, Wang S, Zhu G, Gao T, Chen W, Ci X, Xu W, Xu K, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Têtu B, Fradet Y, Lupien M, Wei GH, Koritzinsky M, Bristow RG, Fleshner NE, Wu X, Shao Y, He C, Berlin A, van der Kwast T, Leong H, Boutros PC, He HH

    The landscape of N6-methyladenosine in localized primary prostate cancer

    Nat Genet 57 (4), 2025.

    DOI PUBMED
  • article Souli I, Lapointe J, Kinsley-Marlie J, Chiquette J, Dorval M, Diorio C, Lauzier S, Audet-Walsh É and Bilodeau S, Côté M, Brisson C, Charette N, Fortier P, Paquette JS, Fradet Y, Savard J, Fradet V, Nabi H

    Feasibility and acceptability of a personalised primary prevention strategy for women and men at high risk of breast and prostate cancer: the 3PC study protocol for a pilot rand…

    BMJ Open 15 (2), 2025.

    DOI PUBMED
  • article Laaraj J, Lachance G, Bergeron A, Fradet Y, Robitaille K, Fradet V

    New insights into gut microbiota-prostate cancer crosstalk

    Trends Mol Med 31 (9), 2025.

    DOI PUBMED
  • article De Santis M, Palou Redorta J, Nishiyama H, Krawczyński M, Seyitkuliev A, Novikov A, Guerrero-Ramos F, Zukov R, Kato M, Kawahara T, Goeman L, Puente J, Hellmis E, Powles T, Radziszewski P, Gust KM, Vasey P, Bigot P, Fradet Y, Hunting J, Armstrong J, Boulos S, Hois S, Shore ND and

    Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

    Lancet 406 (10516), 2025.

    DOI PUBMED
  • article Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES

    Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

    Prostate Cancer Prostatic Dis 28 (2), 2025.

    DOI PUBMED
  • article Garneau CA, Marcotte N, Lacombe L, Fradet Y, Fradet V, Pouliot F, Toren P, Lodde M

    Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC

    Can Urol Assoc J 18 (2), 2024.

    DOI PUBMED